Jing, G., Jo, S., & Shalev, A. (2024, October). A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging. Frontiers in Endocrinology.
Chicago Style (17th ed.) CitationJing, Gu, SeongHo Jo, and Anath Shalev. "A Novel Class of Oral, Non-immunosuppressive, Beta Cell-targeting, TXNIP-inhibiting T1D Drugs Is Emerging." Frontiers in Endocrinology Oct. 2024.
MLA (9th ed.) CitationJing, Gu, et al. "A Novel Class of Oral, Non-immunosuppressive, Beta Cell-targeting, TXNIP-inhibiting T1D Drugs Is Emerging." Frontiers in Endocrinology, Oct. 2024.
Warning: These citations may not always be 100% accurate.